EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Executive Dysfunction and Disability in SPMS : Predictive Value of the Frontal Assessment Battery in the UCLH MS ‐ STAT2 Cohort

Charles Wade iD, Anisha Doshi, Sean Apap Mangion iD, Tom Williams iD, Alessia Bianchi, Floriana De Angelis, Sarah Wright iD, Nevin John iD, Alberto Calvi, Marie Braisher, James Blackstone, Jennifer Nicholas und 2 weitere

European Journal of Neurology · 2025

DOI: 10.1111/ene.70286 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Charles Wade und 13 weiteren Autor:innen. Beteiligte Einrichtung: Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, Universi…. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Executive Function, Multiple Sclerosis, Chronic Progressive, Neuropsychological Tests. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Cognitive impairment is common in secondary progressive multiple sclerosis (SPMS), with executive dysfunction disproportionately so. The frontal assessment battery (FAB) is a bedside test assessing executive function. This study explores the distribution of FAB scores in a large SPMS cohort and their associations with disability.

Methods

Data were analysed from 294 participants in a cognitive substudy of the MS‐STAT2 trial (NCT03387670). Associations between baseline FAB scores, ambulation status (Expanded Disability Status Scale [EDSS] < 6.0 vs. ≥ 6.0) and other disability measures were assessed using generalised linear models, adjusting for age, education, gender and disease duration. FAB performance was also compared against other cognitive tests (SDMT, CVLT‐II, BVMT‐R).

Results

23.8% of participants scored the FAB maximum of 18; 29.9% scored below the clinical threshold of 16. FAB scores showed moderate correlations with SDMT ( ρ = 0.46), CVLT‐II ( ρ = 0.36) and BVMT‐R ( ρ = 0.43), and participants scoring < 16 were significantly more likely to be impaired across these cognitive domains ( p < 0.001). Lower baseline FAB scores were significantly associated with higher EDSS, slower T25FW and reduced manual dexterity (9HPT) (all p < 0.005) at baseline and longitudinally, with performance comparable to other validated cognitive tests.

Conclusions

We present a large cohort of FAB scores in the SPMS population. Lower FAB scores are associated with both concurrent and future disability and may offer a scalable tool for identifying individuals at greater risk of progression and a robust trial outcome measure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cognitive DysfunctionExecutive FunctionMultiple Sclerosis, Chronic ProgressiveNeuropsychological TestsAdultFemaleHumansMaleMiddle AgedCohort StudiesDisability EvaluationPredictive Value of Tests

Stichwörter der Autor:innen

clinical trialscognitionfrontal assessment batterysecondary progressive multiple sclerosis

Autor:innen und Institutionen

  • Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK.
  • Comprehensive Clinical Trials Unit, University College London, London, UK.
  • Department of Medical Statistics, London School of Hygiene and Tropical Medicine, University College London, London, UK.
  • National Institute for Health Research, University College London Hospitals, Biomedical Research Centre, London, UK.

ORCID-Profile: Charles Wade, Sean Apap Mangion, Tom Williams, Sarah Wright, Nevin John

Förderung

  • National Institute for Health and Care Research

Zitieren

APA

Wade, C., Doshi, A., Mangion, S. A., Williams, T., Bianchi, A., De Angelis, F., Wright, S., John, N., Calvi, A., Braisher, M., Blackstone, J., Nicholas, J., Chataway, J., & UCL MS‐STAT2 Investigators (2025). Executive Dysfunction and Disability in SPMS : Predictive Value of the Frontal Assessment Battery in the UCLH MS ‐ STAT2 Cohort. European Journal of Neurology. https://doi.org/10.1111/ene.70286

Vancouver

Wade C, Doshi A, Mangion SA, Williams T, Bianchi A, De Angelis F, et al. Executive Dysfunction and Disability in SPMS : Predictive Value of the Frontal Assessment Battery in the UCLH MS ‐ STAT2 Cohort. European Journal of Neurology. 2025. doi:10.1111/ene.70286

BibTeX
@article{Wade2025,
  author = {Wade, Charles and Doshi, Anisha and Mangion, Sean Apap and Williams, Tom and Bianchi, Alessia and De Angelis, Floriana and Wright, Sarah and John, Nevin and Calvi, Alberto and Braisher, Marie and Blackstone, James and Nicholas, Jennifer and Chataway, Jeremy and UCL MS‐STAT2 Investigators, UCL MS‐STAT2 Investigators},
  title = {Executive Dysfunction and Disability in SPMS : Predictive Value of the Frontal Assessment Battery in the UCLH MS ‐ STAT2 Cohort},
  journal = {European Journal of Neurology},
  year = {2025},
  doi = {10.1111/ene.70286}
}
Kostenlos starten →